Ensign Peak Advisors’s Albireo Pharma Inc ALBO Stock Holding History

Ensign Peak Advisors’s Portfolio ALBO Stock Details ALBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-13,090	Closed	-$283K	–	1804
2022 Q4	$283K	Buy	13,090 +6,450	+97%	+$136K	﹤0.01%	1715
2022 Q3	$129K	Hold	6,640	–	–	﹤0.01%	2023
2022 Q2	$132K	Buy	6,640 +1,210	+22%	+$31.9K	﹤0.01%	1911
2022 Q1	$162K	Hold	5,430	–	–	﹤0.01%	1938
2021 Q4	$126K	Buy	+5,430	New	+$144K	﹤0.01%	2022

Other funds holding ALBO

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Ensign Peak Advisors's ALBO Position: Q1 2023 in Review

Ensign Peak Advisors sold out of Albireo Pharma Inc (ALBO) in Q1 2023, closing a stake of 13,090 shares — an estimated $283K sold.

Ensign Peak Advisors first reported a position in ALBO in Q4 2021 and held it in 5 quarters. The position peaked at $283K in Q4 2022. 3 funds tracked by Wall St. Rank hold ALBO as of Q1 2023.

Ensign Peak Advisors reported no remaining Albireo Pharma Inc position as of Q1 2023 after selling out during the quarter.
Ensign Peak Advisors sold 13,090 Albireo Pharma Inc shares in Q1 2023, an estimated $283K.
Ensign Peak Advisors first reported a position in Albireo Pharma Inc in Q4 2021 and held it in 5 quarters.
Ensign Peak Advisors's Albireo Pharma Inc position peaked at $283K in Q4 2022.
3 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q1 2023.

Based on Ensign Peak Advisors's 13F filing for Q1 2023, filed 15 May 2023.